Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2012 1
2017 1
2018 1
2019 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Refractory Thyroid Gland Medullary Carcinoma"
Page 1
Molecular basis and targeted therapy in thyroid cancer: Progress and opportunities.
Zhang L, Feng Q, Wang J, Tan Z, Li Q, Ge M. Zhang L, et al. Biochim Biophys Acta Rev Cancer. 2023 Jul;1878(4):188928. doi: 10.1016/j.bbcan.2023.188928. Epub 2023 May 29. Biochim Biophys Acta Rev Cancer. 2023. PMID: 37257629 Free article. Review.
However, recurrence or tumor metastasis remains the main challenge in the management of anaplastic thyroid cancer (ATC) and radioiodine (RAI) radioactive iodine-refractory differentiated thyroid cancer (RR-DTC). Several multi-tyrosine kinase inhibitors (MKIs) …
However, recurrence or tumor metastasis remains the main challenge in the management of anaplastic thyroid cancer (ATC) and radioiodi …
Update on thyroid cancer treatment.
Regalbuto C, Frasca F, Pellegriti G, Malandrino P, Marturano I, Di Carlo I, Pezzino V. Regalbuto C, et al. Future Oncol. 2012 Oct;8(10):1331-48. doi: 10.2217/fon.12.123. Future Oncol. 2012. PMID: 23130931 Review.
Advanced medullary thyroid carcinomas may also be refractory to conventional therapies and novel kinase inhibitors may also be useful to control tumor progression in certain patients. Novel evidence is emerging that thyroid cancer is a stem cell diseas …
Advanced medullary thyroid carcinomas may also be refractory to conventional therapies and novel kinase inhibitors may …
Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls.
Beukhof CM, Brabander T, van Nederveen FH, van Velthuysen MF, de Rijke YB, Hofland LJ, Franssen GJH, Fröberg LAC, Kam BLR, Visser WE, de Herder WW, Peeters RP. Beukhof CM, et al. BMC Cancer. 2019 Apr 5;19(1):325. doi: 10.1186/s12885-019-5540-5. BMC Cancer. 2019. PMID: 30953466 Free PMC article.
BACKGROUND: For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine kinase inhibitors result in grade 3-4 adverse events in a large number of patients. ...METHODS: Retrospective evaluation of treatment effec …
BACKGROUND: For progressive metastatic medullary thyroid carcinoma (MTC), the available treatment options with tyrosine …
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Ito Y, Onoda N, Ito KI, Sugitani I, Takahashi S, Yamaguchi I, Kabu K, Tsukada K. Ito Y, et al. Thyroid. 2017 Sep;27(9):1142-1148. doi: 10.1089/thy.2016.0621. Epub 2017 Jul 24. Thyroid. 2017. PMID: 28635560 Free PMC article. Clinical Trial.
BACKGROUND: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic thyroid carcinoma (ATC) are still limited in Japan, even though vandetanib for MTC and lenvatinib for MTC and ATC have been appr …
BACKGROUND: Therapeutic options for treating advanced or metastatic medullary thyroid carcinoma (MTC) and anaplastic …
Early prediction of lenvatinib treatment efficacy by using (18)F-FDG PET/CT in patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment: a protocol for a non-randomized single-arm multicenter observational study.
Takeuchi S, Shiga T, Hirata K, Taguchi J, Magota K, Ariga S, Gouda T, Ohhara Y, Homma R, Shimizu Y, Kinoshita I, Tsuji Y, Homma A, Iijima H, Tamaki N, Dosaka-Akita H. Takeuchi S, et al. BMJ Open. 2018 Aug 30;8(8):e021001. doi: 10.1136/bmjopen-2017-021001. BMJ Open. 2018. PMID: 30166292 Free PMC article.
INTRODUCTION: Lenvatinib, an oral molecular targeted drug, is used to treat patients with unresectable or advanced thyroid carcinoma that is refractory to radioiodine treatment. Effective methods for evaluating molecular targeted drugs are a critical unmet ne …
INTRODUCTION: Lenvatinib, an oral molecular targeted drug, is used to treat patients with unresectable or advanced thyroid carcino …
Molecular elements of apoptosis-regulating pathways in follicular thyroid cells: mining for novel therapeutic targets in the treatment of thyroid carcinoma.
Sarlis NJ, Gourgiotis L. Sarlis NJ, et al. Curr Drug Targets Immune Endocr Metabol Disord. 2004 Sep;4(3):187-98. doi: 10.2174/1568008043339866. Curr Drug Targets Immune Endocr Metabol Disord. 2004. PMID: 15379722 Review.
Recent advances in molecular techniques have shed light upon elements of the above pathways in assorted malignancies, including non-medullary thyroid carcinoma (ThyrCa). A subgroup of ThyrCa patients is (or becomes over time) refractory to standard tre …
Recent advances in molecular techniques have shed light upon elements of the above pathways in assorted malignancies, including non-medul …